autoimmune

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Abatacept (CTLA4Ig) is a soluble fusion protein composed of the extracellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains), functioning as a selective T-cell co-stimulation modulator and a protein drug for autoimmune diseases.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

PD-1 PD-L1-IN-20 is a small molecule inhibitor of PD-1 PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1 PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.

Tabalumab (LY2127399) is a humanised monoclonal antibody targeting BAFF that neutralises both soluble and membrane-bound forms of BLyS and affects B-cell populations, and can be used for research into autoimmune diseases such as rheumatoid arthritis, kidney failure, and systemic lupus erythematosus.

Epratuzumab (AMG 41) is a humanized monoclonal antibody targeting CD22, also a tumor imaging agent that induces CD22 phosphorylation. It is used in autoimmune disease research.

Perakizumab (RG4934) is a humanized monoclonal antibody targeting IL-17A, used in the study of psoriatic arthritis and other autoimmune diseases.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Vobarilizumab (ALX-0061) is a humanized, specific monoclonal antibody targeting IL-6R and albumin (ALB), consisting of an anti-IL-6R domain and an anti-human albumin domain, used in the study of rheumatoid arthritis and other autoimmune diseases.

Afasevikumab (RG 7624) is a fully humanised monoclonal antibody that targets and neutralises IL-17A and IL-17F, and can be used to study autoimmune diseases and inflammation.

Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Tibulizumab (LY 3090106), a tetravalent bispecific monoclonal antibody, selectively binds to B-cell activating factor (BAFF) and IL-17A with dissociation constants (Kd) of 60 pM and 14 pM, respectively. This specificity renders it a valuable tool for autoimmune disease research.

Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist that inhibits T-cell proliferation, offering potential therapeutic applications for kidney transplantation and autoimmune disease research [1].

Melredableukin alfa (RO-7049665) is a fusion protein consisting of a human IgG1-κ and a mutated human interleukin 2 (IL2 mutein), connected by a peptide linker, and is being researched for potential applications in autoimmune hepatitis and ulcerative colitis [1].

Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis.

K1-70 is a humanized antibody targeting TSHR, used in the study of autoimmune diseases and endocrine disorders.

Dapirolizumab is an anti-CD40 monoclonal antibody used in research on systemic lupus erythematosus (SLE) and other autoimmune diseases.

Temtokibart is a humanized monoclonal antibody targeting IL22RA1, used in autoimmune and inflammatory disease research.

Batoclimab (RVT-1401) is a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn) with high affinity for the IgG-binding site on FcRn, and by competitively binding to this site, Batoclimab effectively blocks FcRn-mediated recycling of immunoglobulin G (IgG), resulting in the enhanced degradation of IgG and subsequent reductions in circulating IgG levels, making it a candidate compound for research in autoimmune diseases such as myasthenia gravis and thyroid eye disease.

Tregalizumab, a humanized IgG1-type monoclonal antibody targeting CD4, selectively activates regulatory T cells (Tregs) with suppressive functions in vitro and has potential applications in researching autoimmune diseases (due to inadequate Treg activity) and allergies [1] [2] [3].